Table 1 |.
Baseline participant characteristics, by arm
| Placebo n = 90 | Valsartan n = 88 | |
|---|---|---|
| Mean age*, years | 23.5 (10.1) | 23.1 (10.1) |
| 18 years of age or younger, n (%) | 39 (43%) | 38 (43%) |
| Pre-puberty*, n (%) | 20 (22%) | 19 (22%) |
| Female*, n (%) | 35 (39%) | 34 (39%) |
| White*, n (%) | 88 (98%) | 85 (97%) |
| Black, n (%) | 0 | 3 (3%) |
| Unknown, n (%) | 2 (2%) | 0 |
| Hispanic, n (%) | 21 (23%) | 15 (17%) |
| Sarcomeric gene*, n (%) | ||
| MYH7 | 36 (40%) | 25 (28%) |
| MYBPC3 | 44 (49%) | 47 (53%) |
| TNNT2 | 3 (3%) | 5 (6%) |
| TNNI3 | 2 (2%) | 3 (3%) |
| TPM1 | 1 (1%) | 4 (5%) |
| MYL2 | 1 (1%) | 1 (1%) |
| MYL3 | 2 (2%) | 1 (1%) |
| ACTC | 1 (1%) | 2 (2%) |
| Mean BSA, m2 | 1.85 (0.35) | 1.82 (0.34) |
| Mean BMI* | 25.6 (5.9) | 25.0 (5.6) |
| Systolic blood pressure*, mmHg | 118 (13) | 118 (10) |
| Diastolic blood pressure, mmHg | 69 (11) | 68 (10) |
| NYHA*: Class I, n (%) | 84 (93%) | 80 (91%) |
| Class II, n (%) | 6 (7%) | 8 (9%) |
| BSA-adjusted z-score for maximum LV wall thickness (participants ≤18 years) | 8.1 (4.6) | 8.2 (5.1) |
| Maximum LV wall thickness, mm (participants >18 years) | 16.4 (3.4) | 17.9 (4.7) |
| LVEF*, % | 66.3 (7.2) | 66.1 (5.8) |
| Beta blocker use*, n (%) | 14 (16%) | 18 (20%) |
| Calcium channel blocker use*, n (%) | 1 (1%) | 4 (5%) |
Numbers are mean and standard deviation, unless otherwise indicated.
*
Variables pre-specified to be adjusted in the analysis model. Because of sparse categories, race was dichotomized to white versus non-white, and genotype was dichotomized to thick filament genes (MYBPC3, MYH7, MYL2 or MYL3) versus thin filament genes (ACTC, TNNT2, TNNI3 or TPM1). One participant in the placebo group was missing LVEF.